Evolving Practices for Myelodysplastic Syndromes (MDS): Highlights from ASH 2024 and Beyond - Episode 6

Clinical Insights: Key Data Presented at ASH 2024 in MDS

, ,

Panelists discuss how oral decitabine/cedazuridine demonstrated meaningful clinical activity in patients with TP53-mutated myelodysplastic syndromes (MDS), with a 31% complete response rate and 16.1-month median overall survival, representing an important treatment advance for this traditionally poor-prognosis molecular subgroup.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Evolving Horizons: MDS Diagnosis and Risk Stratification in 2024
    EP. 2: MDS Treatment Strategies: From Risk Assessment to Transplantation
    EP. 3: Introducing Hypomethylating Agents for Patients With MDS
    EP. 4: ASCERTAIN Trial: Key Data of Oral Decitabine and Cedazuridine in MDS
    EP. 5: Comparison of Oral vs Intravenous Hypomethylating Agents in the Treatment of MDS
    Now Viewing
    EP. 6: Clinical Insights: Key Data Presented at ASH 2024 in MDS
    EP. 7: A Deep Dive Into Treatment Approaches for Patients With MDS by Risk Status
    EP. 8: Future Horizons in the Treatment of Myelodysplastic Syndromes

    Video content above is prompted by the following:

    • Can you share any key takeaways or additional data updates surrounding MDS presented at ASH 2024?
    • Oral decitabine/cedazuridine in MDS and TP53 mutations.

    x